Weekly cisplatin chemotherapy dosing versus triweekly chemotherapy with concurrent radiation for head and neck squamous cell carcinoma.

Abstract

Triweekly high-dose cisplatin (100 mg/m² ) with concurrent radiation therapy is the current standard of care in the definitive or appropriate postoperative setting in head and neck squamous cell carcinoma (HNSCC). We compared triweekly 100 mg/m² with alternative weekly 40 mg/m² and weekly <40 mg/m² cisplatin regimens. From 2011 to 2016, 163 patients received concurrent cisplatin and intensity-modulated radiotherapy for locally advanced HNSCC. Primary endpoints were overall survival (OS) and progression-free survival. Cisplatin weekly <40 mg/m² showed inferior OS outcomes when compared to weekly 40 mg/m² (P = 0.084) and triweekly 100 mg/m² (P = 0.04) regimens. Our study displayed inferior outcomes with weekly cisplatin doses under 40 mg/m² , suggesting the inferiority of low-dose weekly chemotherapy and the need for ongoing randomized trials to further explore 40 vs 100 mg/m² chemotherapy regimens.